Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.

The American journal of medicine 20120401

Evaluation of treatment continuation with alosetron by IBS-D severity criteria.

Current medical research and opinion 20120301

Quality of life in patients with irritable bowel syndrome.

Journal of clinical gastroenterology 20110801

The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

Drug safety 20110701

Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.

Current medical research and opinion 20110301

Peripherally acting therapies for the treatment of irritable bowel syndrome.

Gastroenterology clinics of North America 20110301

An electrochemical microfluidic platform for human P450 drug metabolism profiling.

Analytical chemistry 20101215

In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.

Journal of chemical information and modeling 20100726

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.

The American journal of gastroenterology 20100401

Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.

Expert review of gastroenterology & hepatology 20100201

Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.

British journal of pharmacology 20091101

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.

The American journal of gastroenterology 20090701

Intracolonical administration of protease-activated receptor-2 agonists produced visceral hyperalgesia by up-regulating serotonin in the colon of rats.

European journal of pharmacology 20090315

Pathogenesis and management of irritable bowel syndrome.

Tropical gastroenterology : official journal of the Digestive Diseases Foundation 20090101

Increased 5-hydroxytryptamine mediates post-inflammatory visceral hypersensitivity via the 5-hydroxytryptamine 3 receptor in rats.

Digestive diseases and sciences 20081101

Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study.

Alimentary pharmacology & therapeutics 20080801

Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.

European journal of pharmacology 20080610

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20080501

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.

Clinical therapeutics 20080501

Clinical practice. Irritable bowel syndrome.

The New England journal of medicine 20080417

Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.

The American journal of gastroenterology 20080401

Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.

European journal of pharmacology 20071114

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

The American journal of gastroenterology 20070801

Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070801

The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.

Xenobiotica; the fate of foreign compounds in biological systems 20070801

The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human.

Xenobiotica; the fate of foreign compounds in biological systems 20070801

Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia.

Pain 20070701

Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070701

Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.

Journal of pharmacological sciences 20070701

[Novel therapeutic approaches in the treatment of irritable bowel syndrome].

Orvosi hetilap 20070520

[Drug treatment of irritable bowel syndrome: an unmet need].

Gastroenterologia y hepatologia 20070301

The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme.

Alimentary pharmacology & therapeutics 20070201

Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070201

Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia.

Pain 20061215

Irritable bowel syndrome: a practical review.

Southern medical journal 20061101

A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme.

Alimentary pharmacology & therapeutics 20060901

[Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].

Nihon rinsho. Japanese journal of clinical medicine 20060801

Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

The American journal of gastroenterology 20060501

Alosetron: ischemic colitis and serious complications of constipation.

The American journal of gastroenterology 20060501

Drug withdrawals and the lessons within.

Current opinion in drug discovery & development 20060101

Acute hepatitis associated with alosetron (Lotronex).

Journal of clinical gastroenterology 20050801

Novelty stress increases fecal pellet output in mongolian gerbils: effects of several drugs.

Journal of pharmacological sciences 20050801

Intestinal propulsion of a solid non-deformable bolus.

Journal of theoretical biology 20050707

Pharmacogenomics and functional gastrointestinal disorders.

Pharmacogenomics 20050701

The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20050401

Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20050401

Characterization of the metabolites of alosetron in experimental animals and human.

Xenobiotica; the fate of foreign compounds in biological systems 20050201

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

The American journal of gastroenterology 20050101

Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis.

Geriatrics 20050101

[Irritable bowel syndrome: a concise diagnostic and pharmacological therapy review].

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 20050101

Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20041201

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

The American journal of gastroenterology 20041101

Delayed Gastric Emptying in Functional Dyspepsia.

Current treatment options in gastroenterology 20040801

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20040801

Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).

Digestive diseases and sciences 20040801

Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.

Alimentary pharmacology & therapeutics 20040715

Alosetron use drops dramatically with risk management.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040615

Advances in pharmacological treatments of IBS.

Journal of pediatric gastroenterology and nutrition 20040601

Irritable bowel syndrome.

Clinical evidence 20040601

New drugs and dosage forms.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040415

Therapy for irritable bowel syndrome.

The New England journal of medicine 20040318

New options for soothing an irritable bowel.

The Johns Hopkins medical letter health after 50 20040301

Study design issues in irritable bowel syndrome.

Alimentary pharmacology & therapeutics 20040101

5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats.

Journal of pharmacological sciences 20040101

Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?

Drug safety 20040101

Advances in the management of irritable bowel syndrome.

Current gastroenterology reports 20031201

Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.

The American journal of gastroenterology 20031201

Alosetron and irritable bowel syndrome.

Expert opinion on pharmacotherapy 20031101

Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.

The American journal of gastroenterology 20030901

Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.

Cleveland Clinic journal of medicine 20030601

Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.

The American journal of gastroenterology 20030501

Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats.

European journal of pharmacology 20030425

Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.

Alimentary pharmacology & therapeutics 20030401

Bad medicine. Why data from drug companies may be hard to swallow.

Scientific American 20030201

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20030201

Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.

BMJ (Clinical research ed.) 20030104

Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.

BMJ (Clinical research ed.) 20030104

Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.

Alimentary pharmacology & therapeutics 20030101

Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?

Cleveland Clinic journal of medicine 20030101

Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response.

The pharmacogenomics journal 20030101

Tegaserod and other serotonergic agents: what is the evidence?

Reviews in gastroenterological disorders 20030101

Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

Drugs 20030101

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.

The American journal of gastroenterology 20021201

Evidence-based position statement on the management of irritable bowel syndrome in North America.

The American journal of gastroenterology 20021101

Systematic review on the management of irritable bowel syndrome in North America.

The American journal of gastroenterology 20021101

New developments in the diagnosis and treatment of irritable bowel syndrome.

Current gastroenterology reports 20021001

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.

Gastroenterology 20021001

FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.

Health news (Waltham, Mass.) 20021001

Alosetron for irritable bowel syndrome.

BMJ (Clinical research ed.) 20020914

FDA advisers warn of more deaths if drug is relaunched.

BMJ (Clinical research ed.) 20020914

Alosetron: a case study in regulatory capture, or a victory for patients' rights?

BMJ (Clinical research ed.) 20020914

From the Food and Drug Administration.

JAMA 20020814

Alosetron (lotronex) revisited.

The Medical letter on drugs and therapeutics 20020805

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.

Gastroenterology 20020801

Contemporary thoughts on the treatment of irritable bowel syndrome.

Managed care interface 20020801

Alosetron to return to market.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020715

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.

Alimentary pharmacology & therapeutics 20020701

FDA allows controversial bowel drug back on to market.

Lancet (London, England) 20020615

FDA advisory panels recommend Lotronex be put back on market.

BMJ (Clinical research ed.) 20020504

Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.

Alimentary pharmacology & therapeutics 20020501

Return of alosetron.

Expert opinion on drug safety 20020501

FDA recommends bringing controversial IBS drug back.

Lancet (London, England) 20020427

Sex and age differences in the pharmacokinetics of alosetron.

British journal of clinical pharmacology 20020301

Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans.

Alimentary pharmacology & therapeutics 20020201

Safety concerns about alosetron.

Archives of internal medicine 20020114

Lotronex withdrawal.

Archives of internal medicine 20020114

FDA approves restricted marketing of Lotronex.

FDA consumer 20020101

Adverse drug reaction update.

Adverse drug reactions and toxicological reviews 20020101

Pharmacological treatment of irritable bowel syndrome--from concept to sales.

The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 20020101

Serotoninergic neuroenteric modulators.

Lancet (London, England) 20011215

Effect of alosetron on theophylline pharmacokinetics.

British journal of clinical pharmacology 20011101

Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.

American journal of physiology. Gastrointestinal and liver physiology 20011001

[Irritable bowel syndrome: diagnostic criteria and recent advancement of its pharmacological management].

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20011001

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

The American journal of gastroenterology 20010901

Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.

The American journal of gastroenterology 20010901

[Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].

Gastroenterologie clinique et biologique 20010901

[Functional intestinal disorders and quality of life].

Gastroenterologie clinique et biologique 20010901

The FDA and The Lancet: an exchange.